Investment Rating - The report maintains an "Outperform" rating for multiple companies in the healthcare sector, including JD Health, WuXi Biologics, Alibaba Health, and others, while China National Pharmaceutical Group is rated "Neutral" [1]. Core Insights - The Hang Seng Healthcare Index rose by 0.6% during the week of May 12-16, 2025, outperforming the Hang Seng Index by 8.6 percentage points year-to-date, with a total increase of 25.0% since the beginning of the year [4][30]. - The internet healthcare sector led gains with a 7.7% increase, while other sectors like CXO/research services and pharmaceutical distribution also saw positive growth [5][31]. - The report highlights that despite external volatility, China's pharmaceutical industry is expected to benefit from domestic policy support for innovation and improving procurement conditions [5][31]. Summary by Sections Weekly Performance Review - The Hang Seng Healthcare Index increased by 0.6%, while the Hang Seng Index rose by 2.1% during the specified week [4][30]. - Year-to-date, the Hang Seng Healthcare Index has outperformed the Hang Seng Index by 8.6 percentage points, with a total increase of 25.0% [4][30]. Sub-sector Performance - Internet healthcare saw a significant increase of 7.7%, followed by CXO/research services at 2.6% and pharmaceutical distribution at 1.3% [5][31]. - The pharmaceutical and biotech sectors faced initial pressure due to an executive order from Trump aimed at reducing prescription drug prices, but valuations recovered by the end of the week [5][31]. Market Dynamics - Trump's executive order on May 12 requires pharmaceutical companies to align U.S. drug prices with those in other developed countries, aiming for "most favored nation" pricing [7][34]. - The report suggests that the impact of this order on Chinese pharmaceutical companies will be limited, as most do not generate direct revenue from the U.S. market [15].